IL294736A - Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them - Google Patents
Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using themInfo
- Publication number
- IL294736A IL294736A IL294736A IL29473622A IL294736A IL 294736 A IL294736 A IL 294736A IL 294736 A IL294736 A IL 294736A IL 29473622 A IL29473622 A IL 29473622A IL 294736 A IL294736 A IL 294736A
- Authority
- IL
- Israel
- Prior art keywords
- hepe
- composition
- subject
- administered
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269280P | 2015-12-18 | 2015-12-18 | |
| PCT/IB2016/001878 WO2017103671A1 (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hepe and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294736A true IL294736A (en) | 2022-09-01 |
Family
ID=57995240
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294736A IL294736A (en) | 2015-12-18 | 2016-12-19 | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them |
| IL318963A IL318963A (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hydroxy-eicosapentaenoic acid and methods of using them |
| IL259846A IL259846A (en) | 2015-12-18 | 2018-06-06 | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318963A IL318963A (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hydroxy-eicosapentaenoic acid and methods of using them |
| IL259846A IL259846A (en) | 2015-12-18 | 2018-06-06 | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9855238B2 (enExample) |
| EP (2) | EP3389647B1 (enExample) |
| JP (4) | JP2018537513A (enExample) |
| KR (6) | KR20230047501A (enExample) |
| CN (2) | CN108697680A (enExample) |
| AR (1) | AR107143A1 (enExample) |
| AU (4) | AU2016370626B2 (enExample) |
| BR (1) | BR122023026625A2 (enExample) |
| CA (2) | CA3008774C (enExample) |
| ES (1) | ES2948444T3 (enExample) |
| IL (3) | IL294736A (enExample) |
| MX (2) | MX379262B (enExample) |
| NZ (1) | NZ744323A (enExample) |
| PH (1) | PH12018501279A1 (enExample) |
| RU (2) | RU2020137883A (enExample) |
| SG (1) | SG11201805149XA (enExample) |
| WO (1) | WO2017103671A1 (enExample) |
| ZA (2) | ZA201804779B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| EP3878835A1 (en) | 2013-11-15 | 2021-09-15 | DS Biopharma Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| EP3325094B1 (en) | 2015-07-21 | 2021-01-06 | Afimmune Limited | Compositions comprising 15(s)-hepe for use in sensitizing cancer cells to radiation therapy |
| KR20230047501A (ko) | 2015-12-18 | 2023-04-07 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US11622495B2 (en) | 2021-06-01 | 2023-04-11 | Gint Co., Ltd. | Method of automatically combining farm vehicle and work machine and farm vehicle |
| CN113855659B (zh) * | 2021-11-24 | 2022-12-23 | 中国人民解放军东部战区总医院 | 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| WO1995009604A1 (en) | 1993-10-01 | 1995-04-13 | R.P. Scherer Corporation | Methods and compositions for dispensing fragrances |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| AU3846801A (en) | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| BR0209749A (pt) | 2001-05-30 | 2004-07-27 | Laxdale Ltd | Coenzima q e epa ou outro ácido graxo essencial |
| KR20110053281A (ko) | 2002-11-22 | 2011-05-19 | 니폰스이산가부시키가이샤 | 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는 조성물 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5504405B2 (ja) * | 2005-06-10 | 2014-05-28 | 国立大学法人山口大学 | 血管病予防に効果を有する食品組成物 |
| CN101523221A (zh) | 2006-08-08 | 2009-09-02 | 利普米克斯科技公司 | 非酒精性脂肪肝病(nafld)和非酒精性脂肪性肝炎(nash)的标记及其使用方法 |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| WO2010134614A1 (ja) * | 2009-05-22 | 2010-11-25 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| WO2012135032A2 (en) | 2011-03-25 | 2012-10-04 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| MX2014004710A (es) | 2011-10-19 | 2014-12-10 | Dignity Sciences Ltd | Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos. |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| CN104114709A (zh) | 2011-11-29 | 2014-10-22 | 尊贵科学有限公司 | 包含20-碳脂肪酸的组合物及其制备和使用方法 |
| RU2664429C2 (ru) | 2012-01-06 | 2018-08-17 | Омтера Фармасьютикалс, Инк. | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| RU2633862C2 (ru) * | 2012-03-30 | 2017-10-18 | Санчилио Энд Компани, Инк. | Композиции сложных эфиров омега-3 жирных кислот |
| ES2606392T3 (es) | 2012-04-04 | 2017-03-23 | Pronova Biopharma Norge As | Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas |
| US10568858B2 (en) * | 2012-05-10 | 2020-02-25 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| SG10201800243XA (en) * | 2013-07-18 | 2018-02-27 | Mochida Pharm Co Ltd | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
| EP3878835A1 (en) | 2013-11-15 | 2021-09-15 | DS Biopharma Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
| SG10202000496XA (en) * | 2014-01-10 | 2020-03-30 | Afimmune Ltd | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN107405324A (zh) | 2015-01-16 | 2017-11-28 | 艾菲穆恩有限公司 | 包含15‑hepe的组合物和其使用方法 |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| EP3325094B1 (en) | 2015-07-21 | 2021-01-06 | Afimmune Limited | Compositions comprising 15(s)-hepe for use in sensitizing cancer cells to radiation therapy |
| KR20230047501A (ko) | 2015-12-18 | 2023-04-07 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
-
2016
- 2016-12-19 KR KR1020237010220A patent/KR20230047501A/ko not_active Ceased
- 2016-12-19 CA CA3008774A patent/CA3008774C/en active Active
- 2016-12-19 RU RU2020137883A patent/RU2020137883A/ru unknown
- 2016-12-19 CA CA3129008A patent/CA3129008A1/en active Pending
- 2016-12-19 KR KR1020187020457A patent/KR20180094516A/ko not_active Ceased
- 2016-12-19 AR ARP160103915A patent/AR107143A1/es not_active Application Discontinuation
- 2016-12-19 JP JP2018531629A patent/JP2018537513A/ja active Pending
- 2016-12-19 KR KR1020247011532A patent/KR20240052856A/ko not_active Ceased
- 2016-12-19 KR KR1020227008483A patent/KR20220038818A/ko not_active Ceased
- 2016-12-19 SG SG11201805149XA patent/SG11201805149XA/en unknown
- 2016-12-19 CN CN201680082030.9A patent/CN108697680A/zh active Pending
- 2016-12-19 RU RU2018126361A patent/RU2737089C2/ru active
- 2016-12-19 EP EP16834282.2A patent/EP3389647B1/en active Active
- 2016-12-19 IL IL294736A patent/IL294736A/en unknown
- 2016-12-19 BR BR122023026625-0A patent/BR122023026625A2/pt not_active Application Discontinuation
- 2016-12-19 KR KR1020257027779A patent/KR20250130433A/ko active Pending
- 2016-12-19 IL IL318963A patent/IL318963A/en unknown
- 2016-12-19 CN CN202110567290.8A patent/CN113230244A/zh active Pending
- 2016-12-19 US US15/383,889 patent/US9855238B2/en active Active
- 2016-12-19 ES ES16834282T patent/ES2948444T3/es active Active
- 2016-12-19 NZ NZ744323A patent/NZ744323A/en unknown
- 2016-12-19 WO PCT/IB2016/001878 patent/WO2017103671A1/en not_active Ceased
- 2016-12-19 MX MX2018007390A patent/MX379262B/es unknown
- 2016-12-19 AU AU2016370626A patent/AU2016370626B2/en active Active
- 2016-12-19 MX MX2021000773A patent/MX394051B/es unknown
- 2016-12-19 KR KR1020207013456A patent/KR20200055154A/ko not_active Ceased
- 2016-12-19 EP EP23158607.4A patent/EP4218736A3/en active Pending
-
2017
- 2017-12-14 US US15/841,363 patent/US10231945B2/en active Active
-
2018
- 2018-06-06 IL IL259846A patent/IL259846A/en unknown
- 2018-06-14 PH PH12018501279A patent/PH12018501279A1/en unknown
- 2018-07-17 ZA ZA2018/04779A patent/ZA201804779B/en unknown
-
2019
- 2019-01-31 US US16/263,486 patent/US20190224154A1/en not_active Abandoned
- 2019-11-27 JP JP2019214063A patent/JP2020063259A/ja active Pending
-
2020
- 2020-11-11 AU AU2020267224A patent/AU2020267224B2/en active Active
-
2021
- 2021-07-15 ZA ZA2021/04969A patent/ZA202104969B/en unknown
- 2021-07-19 JP JP2021118532A patent/JP2021178840A/ja active Pending
-
2022
- 2022-05-20 US US17/750,262 patent/US12274685B2/en active Active
- 2022-12-23 AU AU2022291628A patent/AU2022291628B2/en active Active
-
2023
- 2023-07-21 JP JP2023118782A patent/JP2023153863A/ja active Pending
-
2025
- 2025-03-05 AU AU2025201593A patent/AU2025201593A1/en active Pending
- 2025-03-19 US US19/083,602 patent/US20250281442A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294736A (en) | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| EP3795141B1 (en) | Solid solution compositions | |
| JP2019048843A5 (enExample) | ||
| JP2018514534A5 (enExample) | ||
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| US10695432B2 (en) | Solid solution compositions and use in severe pain | |
| KR20150040338A (ko) | 다발경화증 치료용 조합 요법 | |
| US10363235B2 (en) | Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same | |
| JP2018537513A5 (enExample) | ||
| JP2002520277A (ja) | 不眠症を治療する方法 | |
| US20240207408A1 (en) | Solid Solution Compositions and Use in Severe Pain | |
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| CN103209692A (zh) | 多发性硬化(ms)的新疗法 | |
| EP2341900A1 (en) | A medicinal product and treatment | |
| JP2019529501A (ja) | 可逆的に保護された、チオレート化求電子性脂肪酸としてのプロドラッグ | |
| EP2292218B1 (en) | Topical application of nimesulide and thiocolchicoside | |
| JP2002520300A (ja) | Ｇａｂａ類縁体及び抗ウイルス剤を含んでなる帯状ヘルペスを治療するための医薬組成物 | |
| JP2018527406A (ja) | Ｓ１ｐ受容体モジュレーターを含む組成物 | |
| US20080161404A1 (en) | Bicalutamide for Delivering Increasing Steady State Plasma Levels | |
| WO2019008554A1 (en) | METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | |
| HK1245101B (en) | Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis | |
| WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
| Paragh et al. | ANIMAL MODEL FOR SIMULTANEOUS STUDY OF STATIN-EFFECTS AGAINST HYPERCHOLESTEROLEMIA AND TUMOR DEVELOPMENT | |
| Blom et al. | Rosuvastatin reduces non-HDL-cholesterol and lipoprotein remnants in Fredrickson type III hyperlipoproteinaemia patients | |
| HK1217651B (en) | Solid solution compositions and use in severe pain |